Virtual Issue on Pre-clinical, melanoma therapy

Most recent articles published on Pre-clinical, melanoma therapy [2011] [2010]

Recent Articles Published on Pre-clinical, melanoma therapy

2011

Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease
Julie Charles, Isabelle Templier, Dominique Leroux, Dimitri Salameire, Caroline Robert, Sylvie Lantuejoul and Marie-Therese Leccia

Parsing out the complexity of RAF inhibitor resistance
Martin McMahon

Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis
Tin-Lun Lam, Gabriel K. Y. Wong, Ho-Yin Chow, Hiu-Chi Chong, Tsz-Lung Chow, Sui-Yi Kwok, Paul N. M. Cheng, Denys N. Wheatley, Wai-Hung Lo and Yun-Chung Leung

Mind the BAP
Andrew E. Aplin and Takami Sato

Red hair or not – reassessment of melanoma risk among CDKN2A carriers
Marianne Berwick

Is UV-induced mutation formation in melanocytes different from other skin cells?
Thomas M. Rünger

Uveal Melanoma and GNA11 Mutations: a new piece added to the puzzle
Ahmad Besaratinia and Gerd P. Pfeifer

Artificial skin in perspective: concepts and applications
Carla A. Brohem, Laura B. da Silva Cardeal, Manoela Tiago, María S. Soengas, Silvia B. de Moraes Barros and Silvya

Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
Keith T. Flaherty

Different types of DNA damage play different roles in the etiology of sunlight-induced melanoma
David L. Mitchell and André A. Fernandez

Clinical relevance of SKP2 alterations in metastatic melanoma
Amy E. Rose, Guimin Wang, Douglas Hanniford, Stefano Monni, Ting Tu, Richard L. Shapiro, Russell S. Berman, Anna C. Pavlick, Michele Pagano,Farbod Darvishian, Madhu Mazumdar, Eva Hernando and Iman Osman

Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target
Y. Qin, E. M. E. Verdegaal, M. Siderius, J. P. Bebelman, M. J. Smit, R. Leurs, R. Willemze, C. P. Tensen and S. Osanto

Seasonal variation in the month of birth in teenagers and young adults with melanoma suggests the involvement of early-life UV exposure
Nermine O. Basta, Peter W. James, Alan W. Craft and Richard J. Q. McNally

mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
H. Pópulo, P. Soares, A. Faustino, A. S. Rocha, P. Silva, F. Azevedo and J. M. Lopes

2010

Of swords and ploughshares: Immunosurveillance and inflammation in melanoma
Thomas Tüting 

Oncogenic RAF: a brief history of time 
David Solit and Neal Rosen

PLX4032, a Potent Inhibitor of the B-Raf V600E Oncogene, Selectively Inhibits V600E-positive Melanomas
John T. Lee, Ling Li, Patricia A. Brafford, Marcia Van Den Eijnden, Molly B. Halloran, Katrin Sproesser, Nikolas K. Haass, Keiran S.M. Smalley, James Tsai, Gideon Bollag and Meenhard Herlyn

Quantitative Measurement of Circulating Lymphoid-Specific Helicase (HELLS) Gene Transcript: Potential Serum Biomarker for Melanoma Metastasis
Hye-Eun Kim, James T. Symanowski, Erika E. Samlowski, Jason Gonzales and Byungwoo Ryu

Combined mass spectrometry- and immunohistochemistry-based approach to determine protein expression in archival melanoma – proof of principle
Karim Rezaul, Michael Murphy, Deborah H. Lundgren, Lori Wilson and David K. Han

Melanoma Tissue Microarray (TMA) Cohort and Data Repository
David L. Rimm

Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy
Thomas F. Gajewski

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters 
Noriaki Nakai, Gunther Hartmann, Saburo Kishimoto and Norito Katoh

Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma
Yixiong Zhou, Xin Song, Renbin Jia, Haibo Wang, Liyan Dai, Xiaofang Xu, Ping Gu, Shengfang Ge and Xianqun Fan

Targeting GRP78 to enhance melanoma cell death
Shaun Martin, David S. Hill, James C. Paton, Adrienne W. Paton, Mark A. Birch-Machin, Penny E. Lovat and Chris P.F. Redfern

Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis
Denise Ryan, Mairin Rafferty, Shauna Hegarty, Patrick O’Leary, William Faller, Gabriela Gremel, Michael Bergqvist, Margret Agnarsdottir, Sara Strömberg, Caroline Kampf, Fredrik Pontén, Robert C. Millikan, Peter A. Dervan and William M. Gallaghe

Apoptosis initiation and angiogenesis inhibition: melanoma targets for nanosecond pulsed electric fields
Xinhua Chen, Juergen F. Kolb, R. James Swanson, Karl H. Schoenbach and Stephen J. Beebe

Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma
Yang Wang, Helen Jiang, Derek Dai, Mingwan Su, Magdalene Martinka, Penny Brasher, Yaohua Zhang, David McLean, Junling Zhang, Wency Ip, Gang Li, Xuejun Zhang and Youwen Zho

Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA
Angela M. Keuling, Susan E. Andrew and Victor A. Tron

C-end your drugs using peptide tags
Dan Niculescu-Duvaz, Caroline Springer and Richard Marais

How blocking Raf activates the MAPK pathway
Frank McCormick

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
Ruth Halaban, Wengeng Zhang, Antonella Bacchiocchi, Elaine Cheng, Fabio Parisi, Stephan Ariyan, Michael Krauthammer, James P. McCusker, Yuval Kluger and Mario Sznol

Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis
Meera Shah, John L. Stebbins, Antimone Dewing, Jianfei Qi, Maurizio Pellecchia and Ze’ev A. Ronai

Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease
Julie Charles, Isabelle Templier, Dominique Leroux, Dimitri Salameire, Caroline Robert, Sylvie Lantuejoul and Marie-Therese Leccia

Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson’s disease
Julie Charles, Isabelle Templier, Dominique Leroux, Dimitri Salameire, Caroline Robert, Sylvie Lantuejoul and Marie-Therese Leccia

Genome-wide associations studies for melanoma and nevi
Iwei Yeh and Boris C. Bastian

Preclinical and clinical development of targeted therapy in melanoma: attention to schedule
Keith T. Flaherty and Keiran S. M. Smalley

The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate
Luís Sánchez-del-Campo, María F. Montenegro, Juan Cabezas-Herrera and José Neptuno Rodríguez-López

Public health issues arising from sale of illegal and potentially unsafe ‘tanning chemicals’ 
Veronique Del Marmol, Thomas Luger, Norbert J. Neumann and Jean-Paul Ortonne

Use of liposomes as drug delivery vehicles for treatment of melanoma
Melissa A. Tran, Rebecca J. Watts and Gavin P. Robertson

The PTEN–AKT3 signaling cascade as a therapeutic target in melanoma
SubbaRao V. Madhunapantula and Gavin P. Robertson

BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma
Supriya Gaitonde, Surya K De, Marianna Tcherpakov, Antimone Dewing, Hongbin Yuan, Megan Riel-Mehan, Stan Krajewski, Gavin Robertson, Maurizio Pellecchia and Ze’ev Ronai

MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Veronica Höiom, Rainer Tuominen, Max Käller, Diana Lindén, Afshin Ahmadian, Eva Månsson-Brahme, Suzanne Egyhazi, Klas Sjöberg, Joakim Lundeberg and Johan Hansson

Epigenetic marks in melanoma
Hunter W. Richards and Estela E. Medrano

Dendritic cells in the skin – potential use for melanoma treatment
Sanaa El Marsafy, Martine Bagot, Armand Bensussan and Alain Mauviel

Overcoming barriers to programming a therapeutic cellular immune response to fight melanoma
David Baltimore, Owen N. Witte, Lili Yang, James Economou and Antoni Ribas

Anticipating drug resistance in the MAP kinase pathway
Ronen Marmorstein

TYRO3-mediated regulation of MITF: a novel target in melanoma?
Udo Rudloff and Yardena Samuels

High molecular weight–melanoma-associated antigen as a biomarker of desmoplastic melanoma
Yasufumi Goto, Takaaki Arigami, Rajmohan Murali, Richard A. Scolyer, Atsushi Tanemura, Minoru Takata, Roderick R. Turner, Linhda Nguyen, Tung Nguyen, Donald L. Morton, Soldano Ferone and Dave S.B. Hoon

The PGF2α receptor FP is lost in nevi and melanoma
Alex Fricke, Lindy McClelland and Glynis Scott

Mutated ERBB4: a novel drug target in metastatic melanoma?
Kari Kurppa and Klaus Elenius

Recent advances and hurdles in melanoma immunotherapy 
Camilla Jandus, Daniel Speiser and Pedro Romero